Jonathan R. Strosberg, MD

Jonathan R. Strosberg, MD, of Moffitt Cancer Center, walks through the classification of neuroendocrine neoplasms with Simron Singh, MD, MPH, of Sunnybrook Odette Cancer Centre, and moderator Daniel M. Halperin, MD, of Winship Cancer Institute of Emory University.

Jonathan R. Strosberg, MD, of Moffitt Cancer Center, and Simron Singh, MD, MPH, of Sunnybrook Odette Cancer Centre, offer US and Canadian perspectives on how community clinicians can access multidisciplinary input for neuroendocrine tumors (NETs), moderated by Daniel M. Halperin, MD, of Winship Cancer Institute of Emory University.

Simron Singh, MD, MPH, of Sunnybrook Odette Cancer Centre, explains how a multidisciplinary team sequences surgery, interventional radiology, nuclear medicine, and systemic therapy for patients with neuroendocrine tumors (NETs), in conversation with moderator Daniel M. Halperin, MD, of Winship Cancer Institute of Emory University.

Simron Singh, MD, MPH, of Sunnybrook Odette Cancer Centre, and Jonathan R. Strosberg, MD, of Moffitt Cancer Center, describe the makeup of a multidisciplinary neuroendocrine tumor (NET) team with moderator Daniel M. Halperin, MD, of Winship Cancer Institute of Emory University.

Neuroendocrine tumors rise in incidence, often found incidentally, prompting multidisciplinary diagnosis, somatostatin receptor PET imaging, and evolving radioligand therapy options.

NET cases rise steadily as survival boosts prevalence; experts argue it’s no longer rare, driving urgent demand for more resources and treatments.

Jonathan Strosberg, MD, expands on subgroup analyses of outcomes with 177Lu-edotreotide in the COMPETE trial by tumor origin and prior lines of therapy.

Jonathan R. Strosberg, MD, reviews the clinical implications of PRRT with 177Lu-edotreotide for metastatic gastroenteropancreatic neuroendocrine tumors.

Jonathan Strosberg, MD, discusses how the phase 2 DAREON-5 trial could address questions about the use of DLL3/CD3-targeted agents in SCLC and other NECs.

Jonathan R. Strosberg, MD, discusses the evaluation of cabozantinib vs placebo in patients with advanced gastrointestinal neuroendocrine tumors.

Jonathan Strosberg, MD, discusses safety data for 212Pb-DOTAMTATE in metastatic somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors.

Jonathan R. Strosberg, MD, discusses the need to develop additional targeted therapies in hepatocellular carcinoma.

Jonathan Strosberg, MD, discusse​s retreatment with Lutathera in advanced neuroendocrine tumors.

Jonathan R. Strosberg, MD, discusses the findings from the phase II KEYNOTE-158 trial investigating pembrolizumab in patients with advanced neuroendocrine tumors.

Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, discusses the development of radiolabeled somatostatin analogs in the treatment of patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, shares his insight on the current field of neuroendocrine tumors (NETs).

Jonathan Strosberg, MD, medical oncologist, Department of Gastrointestinal Oncology, section head, Neuroendocrine Division, chair, Gastrointestinal Department Research Program, Moffitt Cancer Center, discusses trials in neuroendocrine tumors (NETs).

Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, discusses the challenges associated with treating neuroendocrine tumors (NETs).

Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, discusses the future of using 177Lu-dotatate therapy to treat patients with neuroendocrine tumors.

​Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, discusses quality of life findings in patients with midgut neuroendocrine tumors.

Jonathan R. Strosberg, MD, associate professor at H. Lee Moffitt Cancer Center, discusses pasireotide as a potential treatment for patients with neuroendocrine tumors.

Jonathan R. Strosberg, MD, medical oncologist, Department of Gastrointestinal Oncology, section head, Neuroendocrine Division, chair, Gastrointestinal Department Research Program, Moffitt Cancer Center, discusses results of the phase III NETTER-1 trial for midgut neuroendocrine tumors.